Although the cost of biomarker testing isn’t cheap, the cost of therapy for patients can be much higher, making it important to conduct these tests to start the right therapy, explained Susan Wescott, RPh, MBA, of Mayo Clinic.
Biomarker testing in oncology isn’t happening enough, and there are a number of reasons why that may be, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic. Removing some of the barriers might not make much of a difference, but others, such as prior authorizations, can give patients a much better chance at survival.
Wescott discussed precision medicine and biomarker-driven oncology care during a session at AMCP Nexus, held October 14-17 in Las Vegas, Nevada.
This transcript has been lightly edited for clarity.
Transcript
How often is biomarker testing being done in oncology and what are the barriers to it being done?
We looked at evidence this morning, for example, that showed only 36% of our patients are receiving the right treatment driven by precision medicine. So, getting that test ordered, done, and then using those results to drive the choice of therapy. We do have a lot of opportunity, though, to increase that number of patients by doing a couple of things. Those include making sure that testing is ordered before therapy is started. Also, maybe teaching our prescribers and our patients why it's important to wait and what the consequences are if you don't wait.
The impact is pretty significant. It's really worth waiting to do that. If there is an urgency to start treatment, there are some options there, like using a platinum doublet, for example. We can do something like that without harming the long-term overall survival of patients.
So, what are the barriers for us just getting there today? I think there's quite a few, and it's everything from sometimes patients aren't being referred to get a biopsy in the first place. That's a really small number of patients, and could we move that needle? Probably not, because there may be some important reasons why they're not going there. For example, they're too sick. Their cancer is too advanced. Maybe a liquid biopsy in those patients would add some information and help us make a better treatment decision. But moving through the stages of testing, sometimes there's not enough test sample available in the biopsy or there are problems with the lab.
But there are things that we can do, barriers that we can remove. One of those would be, prior authorization is sometimes in place where the genetic testing itself. If we were to remove that, if we made that one change, I think that we would give all of our non–small cell lung cancer patients, for example, a better chance of survival right away, by just doing that one thing. It does seem like there should be a prior authorization, the way we used to think, because some of these tests are up to $5000. And that's a lot of money. But if we look at the cost of therapy and the overall cost of care in these patients—drug therapy is $150,000 or more per year—choosing the right therapy really makes a lot of sense, financially.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More